Jean Addington
YOU?
Author Swipe
View article: Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative Open
View article: Shift in sex and age of individuals at a clinical high risk (CHR) for psychosis: relation to differences in recruitment methods and effect on sample characteristics
Shift in sex and age of individuals at a clinical high risk (CHR) for psychosis: relation to differences in recruitment methods and effect on sample characteristics Open
View article: Excitation/inhibition imbalance and conversion to psychosis in the clinical high risk syndrome: Biophysical modeling finds reduced pyramidal cell excitability across EEG paradigms
Excitation/inhibition imbalance and conversion to psychosis in the clinical high risk syndrome: Biophysical modeling finds reduced pyramidal cell excitability across EEG paradigms Open
Background Reduced mismatch negativity (MMN) and P300 event-related potential (ERP) components are widely replicated in schizophrenia and are also observed in individuals at clinical high risk for psychosis (CHR-P) who subsequently convert…
View article: Predictors and Moderators of Long-Term Outcome of Persons at Clinical High Risk for Psychosis: Methods and Preliminary Data
Predictors and Moderators of Long-Term Outcome of Persons at Clinical High Risk for Psychosis: Methods and Preliminary Data Open
Background and Hypothesis Despite significant advances in our understanding of the clinical high risk (CHR) for psychosis state, the longer-term outcomes (5+ years) and the trajectory of diagnoses, symptoms, and psychosocial function have …
View article: Incidence, Prevalence, and Stability of Remission in Individuals With Clinical High Risk for Psychosis
Incidence, Prevalence, and Stability of Remission in Individuals With Clinical High Risk for Psychosis Open
Importance While remission from clinical high risk (CHR) for psychosis is a favorable outcome, it is not well characterized over time. Objective To examine remission incidence, prevalence, and stability, and their association with demograp…
View article: The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures Open
View article: Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program Open
Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual …
View article: Treatment Choices for Youth at Clinical High‐Risk of Psychosis: Methods of an Open Trial
Treatment Choices for Youth at Clinical High‐Risk of Psychosis: Methods of an Open Trial Open
Introduction The number of randomised controlled trials (RCT) that address the treatment of youth at clinical high‐risk (CHR) of developing psychosis is few. What is most needed are clinical trials that consider the heterogenous outcomes o…
View article: Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program Open
Clinical ascertainment and clinical outcome are key features of any large multisite study. In the ProNET and PRESCIENT research networks, the Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ) Clinical Ascert…
View article: Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership® Schizophrenia Program
Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership® Schizophrenia Program Open
Modern research management, particularly for publicly funded studies, assumes a data governance model in which grantees are considered stewards rather than owners of important data sets. Thus, there is an expectation that collected data ar…
View article: Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program
Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program Open
View article: The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program Open
Neuroimaging with MRI has been a frequent component of studies of individuals at clinical high risk (CHR) for developing psychosis, with goals of understanding potential brain regions and systems impacted in the CHR state and identifying p…
View article: Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample Open
Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairmen…
View article: Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barré syndrome
Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barré syndrome Open
Guillain-Barré syndrome is an acute polyradiculoneuropathy in which preceding infections often elicit the production of antibodies that target peripheral nerve antigens, principally gangliosides. Anti-ganglioside antibodies are thought to …
View article: Clinical prediction model for transition to psychosis in individuals meeting At Risk Mental State criteria
Clinical prediction model for transition to psychosis in individuals meeting At Risk Mental State criteria Open
Background The At Risk Mental State (ARMS) (also known as the Ultra or Clinical High Risk) criteria identify individuals at high risk for psychotic disorder. However, there is a need to improve prediction as only about 18% of individuals m…
View article: Delineating empirically plausible causal pathways to suicidality among people at clinical high risk for psychosis.
Delineating empirically plausible causal pathways to suicidality among people at clinical high risk for psychosis. Open
Suicidality is common among people at clinical high risk (CHR) for psychosis. Delineating causal pathways to suicidality and identifying its determinants would inform tailored intervention efforts for these individuals. To this end, we ana…
View article: Predicting conversion to psychosis using machine learning: response to Cannon
Predicting conversion to psychosis using machine learning: response to Cannon Open
Background We previously reported that machine learning could be used to predict conversion to psychosis in individuals at clinical high risk (CHR) for psychosis with up to 90% accuracy using the North American Prodrome Longitudinal Study-…
View article: Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program Open
Background This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical …
View article: Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program Open
Background This paper presents the recruitment sources of clinical high-risk (CHR) and community controls (CC) from the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program, which aims to study various clinical variables and …
View article: Mismatch Negativity as an Index of Auditory Short-Term Plasticity: Associations with Cortisol, Inflammation, and Gray Matter Volume in Youth at Clinical High Risk for Psychosis.
Mismatch Negativity as an Index of Auditory Short-Term Plasticity: Associations with Cortisol, Inflammation, and Gray Matter Volume in Youth at Clinical High Risk for Psychosis. Open
Mismatch negativity (MMN) event-related potential (ERP) component reduction, indexing N-methyl-D-aspartate receptor (NMDAR)-dependent auditory echoic memory and short-term plasticity, is a well-established biomarker of schizophrenia that i…
View article: Cognitive-Behavioural Social Skills Training: Mediation of Treatment Outcomes in a Randomized Controlled Trial for Youth at Risk of Psychosis: L’entraînement aux compétences sociales cognitivo-comportementales : variables médiatrices des résultats thérapeutiques dans le cadre d’un essai clinique randomisé pour les jeunes présentant un risque de psychose
Cognitive-Behavioural Social Skills Training: Mediation of Treatment Outcomes in a Randomized Controlled Trial for Youth at Risk of Psychosis: L’entraînement aux compétences sociales cognitivo-comportementales : variables médiatrices des résultats thérapeutiques dans le cadre d’un essai clinique randomisé pour les jeunes présentant un risque de psychose Open
Objectives Currently, there are no effective treatments for functional outcomes (i.e., role and social) and negative symptoms for youth at clinical high-risk (CHR) for psychosis. Investigations into possible mechanisms that may contribute …
View article: Attention Deficit Hyperactivity Disorder among Youth at Clinical High Risk of Psychosis
Attention Deficit Hyperactivity Disorder among Youth at Clinical High Risk of Psychosis Open
Attention Deficit Hyperactivity Disorder (ADHD) affects a significant proportion of the population and is associated with numerous adverse outcomes including lower educational attainment, occupational challenges, increased substance use, a…
View article: Cognitive subtypes in youth at clinical high risk for psychosis
Cognitive subtypes in youth at clinical high risk for psychosis Open
Introduction Schizophrenia is a mental health condition that severely impacts well-being. Cognitive impairment is among its core features, often presenting well before the onset of overt psychosis, underscoring a critical need to study it …
View article: Fetal Gene Regulatory Gene Deletions are Associated with Poor Cognition in Schizophrenia and Community-Based Samples
Fetal Gene Regulatory Gene Deletions are Associated with Poor Cognition in Schizophrenia and Community-Based Samples Open
Objective Schizophrenia is a neurodevelopmental disorder involving clinical and genetic heterogeneity. Multiple recurrent copy number variants (CNVs) increase risk for schizophrenia spectrum disorders (SSD). However, how known risk CNVs an…
View article: Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis
Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis Open
Sex differences have been observed in individuals with schizophrenia and for those at clinical high risk (CHR) for psychosis. However, specific differences in CHR individuals who transition to psychosis remain inconsistent and understudied…
View article: The Complex Latent Structure of Attenuated Psychotic Symptoms: Hierarchical and Bifactor Models of SIPS Symptoms Replicated in Two Large Samples at Clinical High Risk for Psychosis
The Complex Latent Structure of Attenuated Psychotic Symptoms: Hierarchical and Bifactor Models of SIPS Symptoms Replicated in Two Large Samples at Clinical High Risk for Psychosis Open
Background and Hypothesis The Structured Interview for Psychosis-Risk Syndromes (SIPS) and other assessments of psychosis risk define clinical high risk for psychosis (CHR) by the presence of attenuated psychotic symptoms. Despite extensiv…
View article: Race/ethnicity and socioeconomic status as predictors of outcome following family therapy in youth at clinical high risk for psychosis
Race/ethnicity and socioeconomic status as predictors of outcome following family therapy in youth at clinical high risk for psychosis Open
Aim There is limited research on the effects of sociodemographic and socioeconomic factors on treatment outcomes in youth at clinical high risk for psychosis (CHRp). This study examined sociodemographic factors that may affect functional o…
View article: Unique functional neuroimaging signatures of genetic versus clinical high risk for psychosis
Unique functional neuroimaging signatures of genetic versus clinical high risk for psychosis Open
Background 22q11.2 Deletion Syndrome (22qDel) is a copy number variant (CNV) associated with psychosis and other neurodevelopmental disorders. Adolescents at clinical high risk for psychosis (CHR) have subthreshold psychosis symptoms witho…
View article: Issue Information
Issue Information Open
View article: Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies
Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies Open
The results indicate that plasma complement and coagulation regulator levels are prognostic factors of negative symptoms, independent of clinical and demographic prognostic factors. These results suggest complement and coagulation regulato…